Prevnar 13 Sales Data
| Rank 95 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Prevnar 13 U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 95 ( 15) |
$180,661 | -11.69% | 154 | -13.97% |
| Q4 2012 | 80 ( 14) |
$204,585 | 15.24% | 179 | 13.29% |
| Q3 2012 | 94 (10) |
$177,527 | -5.86% | 158 | -5.39% |
| Q2 2012 | 84 (8) |
$188,578 | 5.30% | 167 | 7.74% |
| Q1 2012 | 92 (4) |
$179,085 | -1.16% | 155 | -5.49% |
| Q4 2011 | 88 (11) |
$181,189 | -6.93% | 164 | -7.87% |
| Q3 2011 | 77 ( ) |
$194,677 |  |
178 | |
| Q1 2011 | 60 | $254,201 | |
243 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| February 22, 2012 | Pfizer Statement Regarding CDC's ACIP Discussion of Prevnar 13 for Use in Adults |
| January 3, 2012 | Prevnar 13 Pneumonia Vaccine Approved for Older People |
| January 3, 2012 | FDA Approves Pneumococcal 13 Vaccine |
| November 17, 2011 | FDA Panel Backs Pfizer Vaccine for Adults |
| February 24, 2010 | Successor to Combination Pneumococcal Vaccine Approved |
